Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.20
$17.03M1.19169,979 shs4.12 million shs
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$10.75
-0.3%
$10.76
$10.20
$11.30
$156.52M-0.01121,140 shs3,300 shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.73
-0.6%
$4.84
$0.53
$5.25
$47.62M-1.689,280 shs1,665 shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$11.49
-0.6%
$10.39
$5.35
$16.15
$627.08M1.14672,441 shs185,804 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%+10.54%-68.45%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00%0.00%0.00%0.00%0.00%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%-2.67%+3.96%+18.25%+80.53%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-0.56%-3.00%+5.37%+93.35%-9.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
4.043 of 5 stars
3.60.00.04.82.30.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.29
Buy$23.20102.00% Upside

Current Analyst Ratings Breakdown

Latest HHLA, OPGN, ENZ, and STOK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $35.00
4/9/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/A$1.71 per share6.29($1.19) per shareN/A
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M17.82N/AN/A($11.55) per share-0.41
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$36.56M17.15N/AN/A$4.32 per share2.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$17.69M-$0.14N/AN/AN/A-57.47%-0.35%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$88.98M$0.7914.54N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A
0.03
0.03
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
8.41
8.41

Institutional Ownership

CompanyInstitutional Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
39.24%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.54%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
9.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A14.56 million14.48 millionNot Optionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10054.60 million49.41 millionOptionable

Recent News About These Companies

Stockley named Stoke's new academy manager
STOK Stoke Therapeutics, Inc. - Seeking Alpha
Cantor Fitzgerald Predicts STOK FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

$0.32 -0.06 (-14.83%)
Closing price 04/17/2025
Extended Trading
$0.32 0.00 (0.00%)
As of 04/17/2025 05:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

HH&L Acquisition stock logo

HH&L Acquisition NYSE:HHLA

HH&L Acquisition Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on healthcare or healthcare-related companies in Asian markets. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.73 -0.03 (-0.63%)
As of 07/2/2025 03:50 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$11.48 -0.07 (-0.56%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$11.48 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.